Cargando…

Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm(™)) to Patients Participating in Clinical Trials

Detalles Bibliográficos
Autor principal:	Cummings, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427024/ https://www.ncbi.nlm.nih.gov/pubmed/35542996 http://dx.doi.org/10.14283/jpad.2022.25

Ejemplares similares

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Payment Policy and Competition in the Medicare+Choice Program
por: Pizer, Steven D., et al.
Publicado: (2002)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Diffusion of Medicare's RBRVS and Related Physician Payment Policies
por: McCormack, Lauren A., et al.
Publicado: (1994)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Should Canadian patients look forward to aducanumab for Alzheimer disease?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Impact of Medicare payment policy on home health resources utilization
por: Irvine, Audrey, et al.
Publicado: (1991)

Aducanumab for Alzheimer’s disease: The never‐ending story that nurses should know
por: Petch, Joel, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
por: Gandy, Sam, et al.
Publicado: (2021)

Should practice and policy be revised to allow for risk-proportional payment to human challenge study participants?
por: Jamrozik, Euzebiusz, et al.
Publicado: (2020)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

An Evaluation of the Service Intensity Add-On Payment Policy Reform in the Medicare Hospice Benefit
por: Christian, Thomas, et al.
Publicado: (2021)

Performance of Physician Groups and Hospitals Participating in Bundled Payments Among Medicare Beneficiaries
por: Liao, Joshua M., et al.
Publicado: (2022)

Effect of Medicare Advantage Payments on Dually Eligible Medicare Beneficiaries
por: Atherly, Adam, et al.
Publicado: (2005)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Medicare and Medicaid Physician Payment Incentives
por: Burney, Ira L., et al.
Publicado: (1979)

New Directions for Medicare Payment Systems
por: Goody, Brigid, et al.
Publicado: (1994)

An outlier pool for Medicare HMO payments
por: Beebe, James C.
Publicado: (1992)

Rethinking Medicare Payment Adjustments for Quality
por: Averill, Richard F., et al.
Publicado: (2016)

Trends in Urethral Suspension With Robotic Prostatectomy Procedures Following Medicare Payment Policy Changes
por: Li, Jonathan, et al.
Publicado: (2022)

Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes
por: Taylor, Erin A., et al.
Publicado: (2023)

Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey
por: DiStefano, Michael J., et al.
Publicado: (2022)

Medicare Interim Payment System's Impact on Medicare Home Health Utilization
por: Liu, Korbin, et al.
Publicado: (2003)

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Impact of the Medicare prospective payment system for hospitals
por: Guterman, Stuart, et al.
Publicado: (1986)

Measuring Function for Medicare Inpatient Rehabilitation Payment
por: Carter, Grace M., et al.
Publicado: (2003)

Trends in Medicare Payments for Beneficiaries With Aortic Stenosis
por: van Bakel, Pieter A. J., et al.
Publicado: (2022)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Chief nursing officers’ perspectives on Medicare’s hospital-acquired conditions non-payment policy: implications for policy design and implementation
por: Wald, Heidi, et al.
Publicado: (2012)

Kaiser-Permanente's Medicare Plus Project: A Successful Medicare Prospective Payment Demonstration
por: Greenlick, Merwyn R., et al.
Publicado: (1983)

Vulnerability of Rural Hospitals to Medicare Outpatient Payment Reform
por: Mohr, Penny E., et al.
Publicado: (1999)

Diagnosis-Based Risk Adjustment for Medicare Capitation Payments
por: Ellis, Randall P., et al.
Publicado: (1996)

Quality in Medicare: From Measurement to Payment and Provider to Patient
por: Milgate, Karen, et al.
Publicado: (2005)

Payment Reduction and Medicare Private Fee-for-Service Plans
por: Frakt, Austin B., et al.
Publicado: (2009)

Prospective payment for Medicare hospital capital: Implications of the research
por: Cotterill, Philip G.
Publicado: (1992)

Medicare's prospective payment system: A critical appraisal
por: Coulam, Robert F., et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_neej1d22e7qkolu54k3p2clppi